Sourav Kole, PhD, is a General Partner and Managing Director at Dolby Family Ventures, where he leads the firm’s investments in early-stage life sciences companies, primarily across brain health (neurodegeneration, psychiatry, and neurotech), enabling platform technologies, fertility, and regenerative medicine. He currently sits on the boards of Libra Therapeutics, Montara Therapeutics, Motif Neurotech, MindImmune Therapeutics, and Progentos Therapeutics. Prior to joining DFV, Sourav was at Verily (fka Google Life Sciences) as the business lead for programs and partnerships for a wide-range of next-generation technologies at the convergence of life sciences and data science, including special projects such as Verily’s efforts towards the opioid epidemic and the COVID-19 pandemic. Prior to Verily, Sourav was at Varian (previously, NYSE: VAR), where he enabled the growth and strategic transformation of the company via large scale M&A, co-founded a venture capital arm, grew the ~$250 million China business while working in China, and led the rollup of interventional oncology assets to create a new business unit. Varian was acquired by Siemens Healthineers for $16.4B. Prior to Varian, Sourav built and invested in several healthcare and technology companies. Successful exits include Arterys (acquired by Tempus), Fusion Pharma (previously, NASDAQ: FUSN; then acquired by AstraZeneca), Grail (acquired by Illumina), Health Catalyst (NASDAQ: HCAT), Instructure (NYSE: INST), Lineagen (acquired by Bionano Genomics), Lyft (NASDAQ: LYFT), and Zebra Medical (acquired by Nanox). Sourav started his career as an entrepreneur by founding Xenocor, which continues to commercialize single-use, small footprint laparoscopy enabling widespread access to minimally invasive surgery. Sourav has a PhD in Biomedical Engineering from the University of Utah. His doctoral research focused on developing imaging biomarkers for neurodegenerative diseases, specifically Alzheimer’s Disease.